- UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid
- Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose
- UPNEEQ(R) is available through RVL Pharmaceuticals’ dedicated e-commerce platform, Elevate, which supports subscription ordering by HCPs and RVL Pharmacy patients
- RVL is poised to be an integral player in the global medical aesthetic market, which is estimated to reach $18 billion by 2027
RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis (ptosis, or low-lying eyelids) in adults. The company believes there is significant potential for UPNEEQ(R) to create value for healthcare providers, patients, and shareholders.
“Looking ahead, we believe that UPNEEQ is a significant potential value driver,” noted Brian Markison, RVL’s…
NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
